| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internship, Nonmedical | 3 | 2013 | 19 | 0.820 |
Why?
|
| Education, Pharmacy | 4 | 2015 | 102 | 0.800 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2015 | 373 | 0.740 |
Why?
|
| Schools, Pharmacy | 4 | 2013 | 36 | 0.690 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2021 | 18 | 0.650 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2011 | 25 | 0.630 |
Why?
|
| Heart Failure | 6 | 2018 | 1180 | 0.610 |
Why?
|
| Coronary Disease | 4 | 2003 | 358 | 0.530 |
Why?
|
| Career Choice | 2 | 2015 | 98 | 0.530 |
Why?
|
| Faculty | 2 | 2013 | 56 | 0.520 |
Why?
|
| Fibrinolytic Agents | 4 | 2008 | 377 | 0.510 |
Why?
|
| Pharmacology, Clinical | 1 | 2015 | 13 | 0.490 |
Why?
|
| Anti-Arrhythmia Agents | 8 | 1998 | 98 | 0.480 |
Why?
|
| Anemia | 2 | 2007 | 104 | 0.480 |
Why?
|
| Leadership | 1 | 2015 | 136 | 0.440 |
Why?
|
| Myocardial Infarction | 6 | 2015 | 807 | 0.430 |
Why?
|
| Prescription Fees | 1 | 2012 | 5 | 0.410 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2012 | 16 | 0.400 |
Why?
|
| Aldosterone | 1 | 2011 | 51 | 0.390 |
Why?
|
| Prescription Drugs | 1 | 2012 | 71 | 0.380 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 82 | 0.370 |
Why?
|
| Ticlopidine | 2 | 2009 | 118 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2003 | 277 | 0.360 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2005 | 178 | 0.330 |
Why?
|
| Pharmacy Residencies | 2 | 2021 | 18 | 0.330 |
Why?
|
| Health Personnel | 1 | 2012 | 286 | 0.330 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 51 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 772 | 0.300 |
Why?
|
| Thrombolytic Therapy | 2 | 2001 | 233 | 0.300 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2008 | 189 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 504 | 0.290 |
Why?
|
| Medication Adherence | 2 | 2018 | 335 | 0.290 |
Why?
|
| Cardiac Output, Low | 1 | 2007 | 52 | 0.290 |
Why?
|
| Erythropoietin | 1 | 2007 | 96 | 0.280 |
Why?
|
| Hematinics | 1 | 2007 | 52 | 0.280 |
Why?
|
| Pipecolic Acids | 1 | 2006 | 9 | 0.270 |
Why?
|
| Sulfonamides | 2 | 2006 | 141 | 0.270 |
Why?
|
| Humans | 46 | 2021 | 68618 | 0.270 |
Why?
|
| Thrombin | 1 | 2006 | 117 | 0.260 |
Why?
|
| Thrombocytopenia | 1 | 2006 | 122 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2008 | 202 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 5 | 1998 | 239 | 0.240 |
Why?
|
| Health Care Costs | 1 | 2007 | 346 | 0.230 |
Why?
|
| Anticoagulants | 2 | 2006 | 356 | 0.230 |
Why?
|
| Spironolactone | 1 | 2003 | 13 | 0.230 |
Why?
|
| Cardiovascular Diseases | 4 | 2015 | 940 | 0.230 |
Why?
|
| Peptide Fragments | 1 | 2006 | 483 | 0.230 |
Why?
|
| Treatment Outcome | 7 | 2015 | 7029 | 0.220 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2003 | 101 | 0.220 |
Why?
|
| Hemodynamics | 4 | 2003 | 705 | 0.220 |
Why?
|
| Proteinuria | 1 | 2003 | 136 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 1 | 2003 | 69 | 0.220 |
Why?
|
| Students, Pharmacy | 2 | 2021 | 79 | 0.190 |
Why?
|
| Piperidines | 4 | 1986 | 123 | 0.190 |
Why?
|
| Aspirin | 3 | 2009 | 295 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2003 | 232 | 0.180 |
Why?
|
| Pyridines | 2 | 2015 | 261 | 0.180 |
Why?
|
| Homocysteine | 1 | 1999 | 28 | 0.170 |
Why?
|
| Clinical Trials as Topic | 9 | 2003 | 848 | 0.170 |
Why?
|
| Methysergide | 1 | 1999 | 4 | 0.170 |
Why?
|
| Sumatriptan | 1 | 1999 | 4 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 498 | 0.170 |
Why?
|
| Serotonin Antagonists | 1 | 1999 | 31 | 0.170 |
Why?
|
| Premenopause | 1 | 1999 | 57 | 0.160 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1999 | 34 | 0.160 |
Why?
|
| Vitamins | 1 | 1999 | 134 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 107 | 0.160 |
Why?
|
| Hospitalization | 2 | 2018 | 978 | 0.160 |
Why?
|
| Amiodarone | 2 | 1998 | 21 | 0.150 |
Why?
|
| Hypertension | 4 | 2003 | 1535 | 0.150 |
Why?
|
| Chronic Disease | 3 | 2018 | 1330 | 0.150 |
Why?
|
| Antioxidants | 1 | 1999 | 304 | 0.150 |
Why?
|
| Registries | 1 | 2000 | 733 | 0.140 |
Why?
|
| Drug Interactions | 4 | 2003 | 289 | 0.140 |
Why?
|
| Quinidine | 2 | 1996 | 15 | 0.140 |
Why?
|
| Female | 22 | 2016 | 38074 | 0.140 |
Why?
|
| Antitrichomonal Agents | 1 | 1996 | 5 | 0.140 |
Why?
|
| Pharmacists | 4 | 2021 | 125 | 0.140 |
Why?
|
| Ciprofloxacin | 1 | 1996 | 30 | 0.140 |
Why?
|
| Metronidazole | 1 | 1996 | 28 | 0.130 |
Why?
|
| Patient Care | 2 | 2006 | 61 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2000 | 581 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2021 | 596 | 0.130 |
Why?
|
| Drug Therapy | 2 | 2008 | 71 | 0.130 |
Why?
|
| Receptor, PAR-1 | 1 | 2015 | 30 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2016 | 254 | 0.120 |
Why?
|
| Lactones | 1 | 2015 | 64 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 742 | 0.120 |
Why?
|
| Time Factors | 6 | 2013 | 4655 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 166 | 0.120 |
Why?
|
| Patient Selection | 2 | 2011 | 592 | 0.120 |
Why?
|
| Sotalol | 1 | 1993 | 6 | 0.110 |
Why?
|
| Male | 18 | 2016 | 37321 | 0.110 |
Why?
|
| Aged | 12 | 2011 | 14862 | 0.110 |
Why?
|
| Adult | 14 | 2011 | 21403 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2010 | 4848 | 0.110 |
Why?
|
| Feedback | 1 | 2013 | 90 | 0.110 |
Why?
|
| Preceptorship | 1 | 2013 | 35 | 0.110 |
Why?
|
| Heparin | 2 | 2006 | 205 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2015 | 204 | 0.110 |
Why?
|
| Electric Countershock | 1 | 1993 | 130 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2012 | 12 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2003 | 80 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2009 | 2358 | 0.100 |
Why?
|
| Program Development | 1 | 2013 | 240 | 0.100 |
Why?
|
| Women | 1 | 2012 | 40 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 657 | 0.100 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2011 | 3 | 0.100 |
Why?
|
| Job Satisfaction | 1 | 2012 | 62 | 0.100 |
Why?
|
| Teaching | 1 | 2013 | 169 | 0.100 |
Why?
|
| Acute Disease | 3 | 2018 | 658 | 0.100 |
Why?
|
| Vancomycin | 1 | 2011 | 60 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2012 | 402 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 92 | 0.090 |
Why?
|
| Stents | 2 | 2008 | 657 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2003 | 649 | 0.090 |
Why?
|
| Minority Groups | 1 | 2012 | 197 | 0.090 |
Why?
|
| Benchmarking | 1 | 2010 | 91 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2010 | 11 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 156 | 0.090 |
Why?
|
| Furosemide | 1 | 2010 | 45 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 1993 | 329 | 0.090 |
Why?
|
| Middle Aged | 14 | 2011 | 21147 | 0.090 |
Why?
|
| Curriculum | 1 | 2013 | 575 | 0.080 |
Why?
|
| Risk Factors | 3 | 2018 | 5731 | 0.080 |
Why?
|
| Exanthema | 1 | 2009 | 30 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2016 | 7277 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2011 | 307 | 0.080 |
Why?
|
| Pharmaceutical Services | 2 | 2006 | 47 | 0.080 |
Why?
|
| Mesalamine | 1 | 2008 | 6 | 0.080 |
Why?
|
| Pharmacy | 1 | 1988 | 26 | 0.080 |
Why?
|
| United States | 7 | 2018 | 7367 | 0.080 |
Why?
|
| Myocarditis | 1 | 2008 | 49 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2011 | 2007 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2008 | 172 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2007 | 23 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2002 | 931 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 91 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 193 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 195 | 0.070 |
Why?
|
| Hirudins | 1 | 2006 | 32 | 0.070 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 57 | 0.070 |
Why?
|
| Coronary Artery Bypass | 2 | 2005 | 218 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 240 | 0.070 |
Why?
|
| Arginine | 1 | 2006 | 102 | 0.060 |
Why?
|
| Diltiazem | 3 | 1990 | 26 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 191 | 0.060 |
Why?
|
| Iron | 1 | 2007 | 197 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 161 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 504 | 0.060 |
Why?
|
| American Heart Association | 2 | 2005 | 142 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 1026 | 0.060 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1984 | 4 | 0.060 |
Why?
|
| Coronary Circulation | 2 | 2003 | 136 | 0.060 |
Why?
|
| Hyperkalemia | 1 | 2003 | 21 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 281 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 71 | 0.060 |
Why?
|
| Atherectomy | 1 | 2003 | 7 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2003 | 32 | 0.060 |
Why?
|
| Diuretics | 1 | 2003 | 97 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2005 | 287 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2003 | 238 | 0.050 |
Why?
|
| Dyspnea | 1 | 2003 | 87 | 0.050 |
Why?
|
| Patient Admission | 1 | 2003 | 99 | 0.050 |
Why?
|
| Lidocaine | 1 | 1983 | 36 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 138 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2005 | 403 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2003 | 140 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1619 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2016 | 3705 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 52 | 0.050 |
Why?
|
| Half-Life | 3 | 1993 | 96 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2000 | 32 | 0.050 |
Why?
|
| Ventricular Fibrillation | 2 | 1993 | 85 | 0.050 |
Why?
|
| Vitamin B Complex | 1 | 1999 | 26 | 0.040 |
Why?
|
| Vitamin E | 1 | 1999 | 55 | 0.040 |
Why?
|
| Cardiology | 1 | 2001 | 140 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1753 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2800 | 0.040 |
Why?
|
| Electrocardiography | 4 | 1986 | 601 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1085 | 0.040 |
Why?
|
| Animals | 6 | 2003 | 20881 | 0.040 |
Why?
|
| Probability | 2 | 2010 | 245 | 0.040 |
Why?
|
| Streptokinase | 1 | 1997 | 23 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1997 | 26 | 0.040 |
Why?
|
| Sex Factors | 1 | 2000 | 1266 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.030 |
Why?
|
| Societies, Pharmaceutical | 2 | 2006 | 22 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 1997 | 172 | 0.030 |
Why?
|
| Professional Practice | 2 | 2006 | 47 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1997 | 296 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 84 | 0.030 |
Why?
|
| Peripheral Arterial Disease | 1 | 2015 | 83 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1993 | 160 | 0.030 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1993 | 73 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 563 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1993 | 169 | 0.030 |
Why?
|
| Creatinine | 2 | 2011 | 243 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2015 | 291 | 0.030 |
Why?
|
| Propranolol | 1 | 1993 | 103 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 567 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2015 | 328 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 334 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 215 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1993 | 141 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 1993 | 153 | 0.020 |
Why?
|
| Heart Rate | 4 | 1989 | 568 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2011 | 226 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1993 | 951 | 0.020 |
Why?
|
| Echocardiography | 2 | 1984 | 515 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 70 | 0.020 |
Why?
|
| Cross Infection | 1 | 2011 | 195 | 0.020 |
Why?
|
| Universities | 1 | 2010 | 191 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 265 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.020 |
Why?
|
| Coronary Artery Disease | 2 | 2005 | 696 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 35 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 1987 | 31 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2008 | 53 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1988 | 248 | 0.020 |
Why?
|
| Metformin | 1 | 2008 | 63 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 77 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 1989 | 1738 | 0.020 |
Why?
|
| Research | 1 | 1988 | 214 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1603 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 155 | 0.020 |
Why?
|
| Lipids | 1 | 1988 | 298 | 0.020 |
Why?
|
| Administration, Oral | 2 | 1985 | 411 | 0.020 |
Why?
|
| Clofibric Acid | 1 | 2005 | 12 | 0.020 |
Why?
|
| Niacin | 1 | 2005 | 12 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1745 | 0.020 |
Why?
|
| Certification | 1 | 2006 | 66 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 1988 | 313 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 82 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1988 | 631 | 0.020 |
Why?
|
| Outpatients | 1 | 1986 | 127 | 0.020 |
Why?
|
| Blood Pressure | 3 | 1989 | 1451 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 362 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 182 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 2752 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1140 | 0.020 |
Why?
|
| Data Collection | 1 | 2006 | 420 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1851 | 0.010 |
Why?
|
| Inpatients | 1 | 2005 | 208 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 212 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1983 | 47 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 3259 | 0.010 |
Why?
|
| Catecholamines | 1 | 1983 | 73 | 0.010 |
Why?
|
| Stroke | 1 | 2015 | 2163 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1984 | 340 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1986 | 738 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1984 | 586 | 0.010 |
Why?
|
| Delayed-Action Preparations | 2 | 1989 | 120 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 5717 | 0.010 |
Why?
|
| Adolescent | 2 | 2010 | 8912 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 442 | 0.010 |
Why?
|
| Phenytoin | 1 | 1977 | 27 | 0.010 |
Why?
|
| Tablets | 1 | 1990 | 19 | 0.010 |
Why?
|
| Posture | 1 | 1989 | 107 | 0.010 |
Why?
|
| Venous Pressure | 1 | 1988 | 7 | 0.000 |
Why?
|
| Constriction | 1 | 1988 | 37 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1987 | 47 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1988 | 133 | 0.000 |
Why?
|
| Dogs | 1 | 1988 | 490 | 0.000 |
Why?
|
| Disopyramide | 1 | 1985 | 1 | 0.000 |
Why?
|
| Flecainide | 1 | 1985 | 3 | 0.000 |
Why?
|
| Tachycardia | 1 | 1985 | 53 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1985 | 119 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1985 | 765 | 0.000 |
Why?
|
| Protein Binding | 1 | 1985 | 1027 | 0.000 |
Why?
|
| Heart | 1 | 1985 | 850 | 0.000 |
Why?
|
| Kinetics | 1 | 1977 | 1047 | 0.000 |
Why?
|
| Epilepsy | 1 | 1977 | 336 | 0.000 |
Why?
|